Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy (Review)
- Authors:
- Ting Liu
- Feng Guo
- Xiaomin Zhu
- Xiangge He
- Lin Xie
-
Affiliations: Department of Ophthalmology, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, People's Liberation Army, Chongqing 400042, P.R. China - Published online on: September 27, 2017 https://doi.org/10.3892/etm.2017.5209
- Pages: 5251-5257
This article is mentioned in:
Abstract
 |
|
Schulz M: Dark remedy: the impact of thalidomide and its revival as a vital medicine. BMJ. 322:16082001. View Article : Google Scholar | |
|
Han ZX, Xu J, Wang HM, Ma J, Sun X and Du XP: Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis. Cell Biochem Biophys. 70:361–365. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vargesson N: Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today. 105:140–156. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Teo S, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI and Thomas SD: Thalidomide in the treatment of leprosy. Microbes Infect. 4:1193–1202. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez-Millan B, de la Guardia Diaz R, Roca-Ho H, García-Herrero CM, Lavoie JR, Rosu-Myles M, Gonzalez-Rey E, O'Valle F, Criado G, Delgado M and Menendez P: Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med. 49:e2902017. View Article : Google Scholar : PubMed/NCBI | |
|
Bartlett JB, Dredge K and Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 4:314–322. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, et al: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 58:1033–1045. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 177:1675–1680. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Keifer JA, Guttridge DC, Ashburner BP and Baldwin AS Jr: Inhibition of NF-kappa B activity by thalidomide through suppression of Ikappa B kinase activity. J Biol Chem. 276:22382–22387. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM and Sarno EN: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 168:408–414. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Zuo XX, Gong YH, Zhou YO, Luo H and Xiao XZ: The plasmic translocation and release of high mobility group box chromosomal protein 1 in peripheral blood monocytes of patients with rheumatoid arthritis and the effect of thalidomide. Zhonghua Nei Ke Za Zhi. 47:374–377. 2008.PubMed/NCBI | |
|
Barkin JA, Schonfeld WB and Deshpande AR: Successful use of thalidomide for refractory esophageal Crohn's disease. Am J Gastroenterol. 108:855–857. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fourcade C, Mauboussin JM, Lechiche C, Lavigne JP and Sotto A: Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis. AIDS Patient Care STDS. 28:567–569. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, Ambrozak A, Gütschow M, Chau CH, Vargesson N and Figg WD: Anti-Cancer properties of a novel class of tetrafluorinated thalidomide analogs. Mol Cancer Ther. 14:2228–2237. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee CJ, Kim KW, Lee HM, Nahm FS, Lim YJ, Park JH and Kim CS: The effect of thalidomide on spinal cord ischemia/reperfusion injury in a rabbit model. Spinal Cord. 45:149–157. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G and Stirling DI: Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem. 39:3238–3240. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G and Stirling DI: Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 9:1625–1630. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Leask A and Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J. 18:816–827. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Javelaud D and Mauviel A: Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: Implications for carcinogenesis. Oncogene. 24:5742–5750. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Choe JY, Jung HJ, Park KY, Kum YS, Song GG, Hyun DS, Park SH and Kim SK: Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res. 59:177–188. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Liang CJ, Yen YH, Hung LY, Wang SH, Pu CM, Chien HF, Tsai JS, Lee CW, Yen FL and Chen YL: Thalidomide inhibits fibronectin production in TGF-β1-treated normal and keloid fibroblasts via inhibition of the p38/Smad3 pathway. Biochem Pharmacol. 85:1594–1602. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
George A, Marziniak M, Schäfers M, Toyka KV and Sommer C: Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain. 88:267–275. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Shannon E, Noveck R, Sandoval F and Kamath B: Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Immunopharmacol Immunotoxicol. 30:447–457. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, Galson DL and Lentzsch S: IMiD immunomodulatory compounds block C/EBP-beta translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 117:5157–5165. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Yoon JH, Won HJ, Ji HS, Yuk HJ, Park KH, Park HY and Jeong TS: Isotrifoliol inhibits pro-inflammatory mediators by suppression of TLR/NF-κB and TLR/MAPK signaling in LPS-induced RAW264.7 cells. Int Immunopharmacol. 110–119. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lai CS, Lee JH, Ho CT, Liu CB, Wang JM, Wang YJ and Pan MH: Rosmanol potently inhibits lipopolysaccharide-induced iNOS and COX-2 expression through downregulating MAPK, NF-kappaB, STAT3 and C/EBP signaling pathways. J Agric Food Chem. 57:10990–10998. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S, Sharma S, Goodglick L, Dubinett S and Lichtenstein A: Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood. 107:4484–4490. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, et al: A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res. 11:5504–5514. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Knight R: IMiDs: A novel class of immunomodulators. Semin Oncol. 32 4 Suppl 5:S24–S30. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Teo SK: Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J. 7:E14–E19. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, et al: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 58:1033–1045. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, et al: Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 62:39–49. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Altman A and Villalba M: Protein kinase C-theta (PKC theta): A key enzyme in T cell life and death. J Biochem. 132:841–846. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Payvandi F, Wu L, Naziruddin SD, Haley M, Parton A, Schafer PH, Chen RS, Muller GW, Hughes CC and Stirling DI: Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J Interferon Cytokine Res. 25:604–616. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kim BS, Kim JY, Lee JG, Cho Y, Huh KH, Kim MS and Kim YS: Immune modulatory effect of thalidomide on T cells. Transplant Proc. 47:787–790. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, et al: Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol1. 64:811–821. 2014. View Article : Google Scholar | |
|
Zhu D, Corral LG, Fleming YW and Stein B: Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 57:1849–1859. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P and Bartlett JB: lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 14:4650–4657. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B and Epstein J: Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 100:4162–4168. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM and Zhou YH: Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res. 38:15–27. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Bréant C, Mathivet T, Larrivée B, Thomas JL, et al: Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 16:420–428. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, et al: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia. 15:1950–1961. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y and Okazaki T: Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors and is antagonized by sphingosine-1-phosphate. Blood. 106:125–134. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, et al: Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 69:56–63. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Komorowski J, Jerczyńska H, Siejka A, Barańska P, Ławnicka H, Pawłowska Z and Stepień H: Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA. hy 926 cells. Life sciences. 78:2558–2563. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Jinnin M: Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol. 37:11–25. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Oliver SJ, Moreira A and Kaplan G: Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol. 97:109–120. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Weingärtner S, Zerr P, Tomcik M, Palumbo-Zerr K, Distler A, Dees C, Beyer C, Shankar SL, Cedzik D, Schafer PH, et al: Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 71:1895–1899. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ingen-Housz-Oro S, Ortonne N, Elhai M, Allanore Y, Aucouturier P and Chosidow O: IgG4-related skin disease successfully treated by thalidomide: A report of 2 cases with emphasis on pathological aspects. JAMA Dermatol. 149:742–187. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Selman M, King TE and Pardo A: American Thoracic Society; European Respiratory Society; American College of Chest Physicians: Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 134:136–151. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
SHI Jie, Qiang N-X and YU Min: Clinical research and correlated cytokine study of thalidomide combined with prednisone on idiopathic pulmonary fibrosis. Practical Pharmacy and Clinical Remedies. 10:52012. | |
|
Zhang L and Yang WL: Effect of thalidomide on the expressions of IL-6, TNF-α and TGF-β1 in BALF of elder patients with idiopathic pulmonary fibrosis. Journal of Xian Jiaotong University (Medical Sciences). 5:622–625. 2012. | |
|
Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M, Nakano T and Kubo H: Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol. 179:708–714. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Knobloch J, Jungck D and Koch A: Apoptosis induction by thalidomide: Critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis? Curr Mol Pharmacol. 4:26–61. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, Danoff SK and Lechtzin N: Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: A randomized trial. Ann Intern Med. 157:398–406. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rethinking thalidomide: Environ Health Perspect. 103:1321995. | |
|
Mall JW, Schwenk W, Philipp AW, Büttemeyer R and Pollmann C: Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model. World J Surg. 27:1119–1123. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kruse FE, Joussen AM, Rohrschneider K, Becker MD and Völcker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 236:461–466. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Ribeiro JC, Vagnaldo Fechine F, Ribeiro MZ, Barreiro EJ, Lima LM, Ricardo NM, de Moraes Amaral ME and de Moraes Odorico M: Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits. Ophthalmic Res. 48:177–185. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Abbas A, Khan B, Feroze AH and Hyman GF: Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis. J Pak Med Assoc. 52:476–482. 2002.PubMed/NCBI | |
|
Lee YK and Chung SK: The inhibitory effect of thalidomide analogue on corneal neovascularization in rabbits. Cornea. 32:1142–1148. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Srinivasan S, Perez-Gomez I, O'Donnell C and Batterbury M: Corneal endothelial abnormalities associated with thalidomide toxicity. Cornea. 24:103–105. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Huang YH and Tseng SH: Corneal snowflakes. Lancet. 380:5062012. View Article : Google Scholar : PubMed/NCBI | |
|
Guex-Crosier Y, Pittet N and Herbort CP: The effect of thalidomide and supidimide on endotoxin-induced uveitis in rats. Graefes Arch Clin Exp Ophthalmol. 233:90–93. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Rodrigues GB, Passos GF, Di Giunta G, Figueiredo CP, Rodrigues EB, Grumman A Jr, Medeiros R and Calixto JB: Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. Exp Eye Res. 84:553–560. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Parentin F, Da Pozzo S, Lepore L and Perissutti P: Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child. Ophthalmologica. 215:70–73. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ip M and Gorin MB: Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. Am J Ophthalmol. 122:594–595. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Rabinowitz R, Katz G, Rosner M, Pri-Chen S and Spierer A: The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 246:843–848. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Verma AS and Fitzpatrick DR: Anophthalmia and microphthalmia. Orphanet J Rare Dis. 2:472007. View Article : Google Scholar : PubMed/NCBI | |
|
Ema M, Ise R, Kato H, Oneda S, Hirose A, Hirata-Koizumi M, Singh AV, Knudsen TB and Ihara T: Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide. Reprod Toxicol. 29:49–56. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Christian MS, Laskin OL, Sharper V, Hoberman A, Stirling DI and Latriano L: Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res B Dev Reprod Toxicol. 80:188–207. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zeldis JB, Carter TL, Knight RD and Hui J: Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans. Proc Natl Acad Sci USA. 110:pp. E48192013, View Article : Google Scholar : PubMed/NCBI | |
|
Narita N, Kato M, Tazoe M, Miyazaki K, Narita M and Okado N: Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: Putative animal models for autism. Pediatr Res. 52:576–579. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Elkinson S and McCormack PL: Pomalidomide: First global approval. Drugs. 73:595–604. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lacy MQ: New immunomodulatory drugs in myeloma. Curr Hematol Malig Rep. 6:120–125. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M and Schey SA: Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 141:41–51. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lacy MQ, Kumar SK, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Russell R, et al: Pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed myeloma: Long term follow up and factors predicing outcome in 345 patients. Blood. 120:2012012. | |
|
Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H and Verstovsek S: Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 38:1126–1129. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 357:2133–2142. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 357:2123–2132. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, et al: Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 146:164–170. 2009. View Article : Google Scholar : PubMed/NCBI |
